23 Jul, 2026
According to Straits Research, the global cancer microbiome sequencing market size was valued at $384.25 million in 2025 and is projected to grow from $460.79 million in 2026 to $1,970.77 million by 2034, registering a CAGR of 19.92% during the forecast period 2026–2034.
The human microbiome is a collection of microbes that reside in and on the human body and can affect cancer initiation, progression, and treatment response, including immunotherapy. The influence of microbiomes on cancer could lead to improved diagnostics and treatments. It describes the market for microbiome sequencing in cancer. Increasing attention on the microbiome's potential in the field of cancer, global increases in cancer prevalence, and reducing sequencing costs are the primary market drivers for this industry.
The cancer microbiome sequencing sector is seeing growth as a result of the rising emphasis on the microbiome's potential in the field of cancer, the worldwide rise in cancer prevalence, and the declining cost of sequencing. In addition, biotechnology companies are concentrating on the development of cancer microbiome sequencing solutions for applications such as translational research and diagnostics, thereby assisting researchers and clinicians in uncovering information regarding the microbiome's influence on the manifestation and progression of cancer.
Lack of high-complexity testing centres, particularly in rising and developing nations of Asia-Pacific, the Middle East, and Africa, is impeding market expansion.
In the future, however, an increase in per capita income and government investment will ameliorate the situation.
Biotechnology firms are concentrating on the development of robust cancer microbiome sequencing solutions for applications such as diagnostics and translational research, thereby assisting end-users in elucidating the complexities of the role of human microbiomes in cancer manifestation and progression. The development of cancer microbiome sequencing products and services by enterprises in conjunction with research institutes is anticipated to provide cancer patients with value-based care in the next years, hence fostering market expansion.
The market is split by region into North America, Europe, Asia-Pacific, and LAMEA.
Due to the presence of market leaders like as Illumina, Inc. in the U.S., as well as the high adoption of high-fidelity cancer microbiome sequencing products and services for translational research, North America owns the highest share of the cancer microbiome sequencing market by region. In addition, rising federal funding injections and expanding investments in product development, among others. Aside from this, the Asia-Pacific region is predicted to see the highest CAGR between 2022 and 2030. This is mostly attributable to underlying reasons such as an increase in healthcare knowledge, a stable economy resulting in a greater emphasis on research, and the widespread adoption of improved cancer diagnostics, among others.
sales@straitsresearch.com